Call Options

9 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2023

Aug 23, 2023

BUY
$0.74 - $1.1 $7,992 - $11,880
10,800 New
10,800 $10,000
Q4 2022

Feb 14, 2023

SELL
$1.0 - $58.8 $22,700 - $1.33 Million
-22,700 Reduced 65.8%
11,800 $17,000
Q3 2022

Nov 14, 2022

BUY
$1.32 - $58.0 $45,540 - $2 Million
34,500 New
34,500 $48,000
Q2 2022

Aug 15, 2022

SELL
$1.28 - $2.31 $30,080 - $54,285
-23,500 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$1.82 - $3.5 $9,464 - $18,200
5,200 Added 28.42%
23,500 $54,000
Q4 2021

Feb 14, 2022

BUY
$1.21 - $2.7 $7,018 - $15,660
5,800 Added 46.4%
18,300 $24,000
Q3 2021

Nov 12, 2021

SELL
$2.59 - $3.36 $36,519 - $47,376
-14,100 Reduced 53.01%
12,500 $33,000
Q2 2021

Aug 06, 2021

BUY
$3.11 - $4.87 $10,574 - $16,558
3,400 Added 14.66%
26,600 $92,000
Q1 2021

May 14, 2021

BUY
$3.66 - $7.67 $84,912 - $177,944
23,200 New
23,200 $94,000

Others Institutions Holding GNPX

About Genprex, Inc.


  • Ticker GNPX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,020,300
  • Market Cap $112M
  • Description
  • Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incor...
More about GNPX
Track This Portfolio

Track Wolverine Trading, LLC Portfolio

Follow Wolverine Trading, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wolverine Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Wolverine Trading, LLC with notifications on news.